FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
The U.S. Food and Drug Administration has directed manufacturers of popular GLP-1 receptor agonists — including Ozempic, Wegovy, Zepbound and Mounjaro — to add a warning about non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause sudden vision loss. The label change follows reports of NAION in patients using these drugs for diabetes and obesity. The agency says a causal link has not been established but the potential risk warrants disclosure. Drugmakers must update prescribing information and patient medication guides.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ FDA ordered manufacturers of GLP-1 drugs to add a warning about non-arteritic anterior ischemic optic neuropathy (NAION).
- ✓ Affected drugs include Ozempic, Wegovy, Zepbound and Mounjaro.
- ✓ NAION is a rare condition that can cause sudden, potentially permanent vision loss.
- ✓ FDA stated a causal relationship between GLP-1 use and NAION has not been established.
What changed
FDA mandated a new boxed warning for NAION risk across the entire GLP-1 class, expanding safety labeling beyond prior gastrointestinal and thyroid cautions.
Live updates
-
FDA orders blindness-risk warning on GLP-1 weight-loss drugs
The U.S. Food and Drug Administration has directed manufacturers of popular GLP-1 receptor agonists, including Ozempic, Wegovy, Zepbound and Mounjaro, to add a warning about non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause sudden vision loss. The label change follows reports of NAION in patients using these drugs for diabetes and obesity. The agency says a causal link has not been established but the potential risk warrants disclosure. Drugmakers must update prescribing information and patient medication guides.
Why it matters
GLP-1 drugs have become blockbuster treatments for type 2 diabetes and obesity, with millions of prescriptions written annually. NAION results from reduced blood flow to the optic nerve and can lead to permanent blindness in the affected eye. The FDA's action reflects its standard practice of flagging safety signals even when definitive causation remains unproven, ensuring patients and prescribers can weigh the rare but serious risk against the drugs' metabolic benefits.
What is confirmed
- FDA ordered manufacturers of GLP-1 drugs to add a warning about non-arteritic anterior ischemic optic neuropathy (NAION).
- Affected drugs include Ozempic, Wegovy, Zepbound and Mounjaro.
- NAION is a rare condition that can cause sudden, potentially permanent vision loss.
- FDA stated a causal relationship between GLP-1 use and NAION has not been established.
- Drugmakers must update prescribing information and patient medication guides.
What to watch next
- Publication of updated drug labels and timing of implementation
- FDA release of case-count data or epidemiological analysis supporting the signal
- Statements from Novo Nordisk and Eli Lilly on label compliance and ongoing safety monitoring
confidence 92%Sources used for this update (10)
- www.cnn.com — Breaking News, Latest News and Videos | CNN
- www.dailymail.com — UK Home | Daily Mail Online
- www.yahoo.com — Yahoo
- Financial Times — US regulator orders makers of weight-loss drugs to carry blindness risk warning
- CNN — US FDA orders new eye risk warnings for Ozempic, Zepbound
- NBC News — FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
- Dallas News — FDA adds rare vision-loss warning to popular GLP-1 drugs
- STAT — FDA warns GLP-1 drugs carry potential risk of rare eye condition
- The Washington Post — FDA tells GLP-1 makers to warn of potential vision loss side effect
- health.yahoo.com — The FDA Just Flagged a Rare Vision Risk for GLP-1 Users. Here’s Why It Should Be on Your Radar.
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community